Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CR4A:GR

449.7200 EUR 6.9900 1.58%

As of 13:54:19 ET on 05/22/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CR4A)

Open: 445.9200 High - Low: 449.7200 - 442.1600 Primary Exchange: Berlin
Volume: 0 52-Week Range: 225.2500 - 472.3200 Beta vs NBI: 1.0209

ETF Chart for CR4A

No chart data available.
  • CR4A:GR 442.2670
  • 1D
  • 1M
  • 1Y
442.7300
Interactive CR4A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CR4A

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 2001-11-06 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CR4A

NAV -
Assets (M) (on 2015-05-21) 261.7274
Shares out (M) 0.45
Market Cap (M) 200.45
% Premium -
Average 52-Week % Premium -
Fund Leveraged N

Dividends for CR4A

No dividends reported

Performance for CR4A

1-Month -2.50% 1-Year +101.64%
3-Month +12.63% 3-Year +47.33%
Year To Date +30.35% 5-Year +36.17%
Expense Ratio -

Top Fund Holdings for CR4A

Filing Date: 03/31/2015
Name Position Value % of Total
Biogen Inc 49,500 20,900,880 8.429%
Amgen Inc 105,973 16,939,784 6.832%
Celgene Corp 145,276 16,747,417 6.754%
Gilead Sciences Inc 162,484 15,944,555 6.431%
BioMarin Pharmaceutical Inc 115,444 14,386,631 5.802%
Regeneron Pharmaceuticals Inc 27,000 12,189,960 4.916%
Incyte Corp 130,000 11,915,800 4.806%
Medivation Inc 80,000 10,325,600 4.164%
Vertex Pharmaceuticals Inc 85,000 10,027,450 4.044%
Alexion Pharmaceuticals Inc 52,752 9,141,922 3.687%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil